Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data. (11th August 2021)

• Record Type: Journal Article
• Authors: Paules, Catharine I; Gallagher, Shannon K; Rapaka, Rekha R; Davey, Richard T; Doernberg, Sarah B; Grossberg, Robert; Hynes, Noreen A; Ponce, Philip O; Short, William R; Voell, Jocelyn; Wang, Jing; Yang, Otto O; Wolfe, Cameron R; Lye, David C; Dodd, Lori E; Benson, Constance A
• Is Part Of: Clinical infectious diseases. Volume 74:Number 7(2022)
• Page Start: 1260
• Page End: 1264
• Publication Date: 2021-08-11
• Subjects: COVID-19 -- remdesivir -- ACTT-1; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciab695
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: This post hoc analysis of the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1 (ACTT-1) shows a treatment effect of remdesivir (RDV) on progression to invasive mechanical ventilation (IMV) or death. Additionally, we create a risk profile that better predicts progression than baseline oxygen requirement alone. The highest risk group derives the greatest treatment effect from RDV.